Clinical Research Trials: Pharmaceuticals – John Paul Runyon, PI.


CLINICAL RESEARCH TRIALS: PHARMACEUTICALS — Dr. Runyon, PI

Principal Investigator
MK0633: The Effect of MK 0633 in patients with atherosclerosis (0633-008).

Principal Investigator
APPROVE: The Angiomax Peripheral Procedure Registry of Vascular Events, a prospective, open-label, single-arm study in patients undergoing PPI of the renal, iliac, or femoral vessels to assess bivalirudin as the sole procedural anticoagulant.

Principal Investigator
Calypso Trial: A double-blind, placebo-controlled, multi-center study of Cylexin and prevention of myocardial perfusion injury in patients with acute myocardial infarction treated with primary angioplasty.

Principal Investigator
Gusto III: A randomized trial of Reteplase versus Alterplase for the treatment of acute myocardial infarction.

Principal Investigator
HITTS: An open-label study of Novastan in patients with Heparin-Induced Thrombocytopenia or Heparin- Induced Thrombocytopenia with Thrombosis Syndrome.

Principal Investigator
Prism: A randomized, parallel, double-blind study to investigate the safety and clinical efficacy of MK- 383 versus heparin in patients with unstable angina/non-Qwave myocardial infarction.

Principal Investigator
Pursuit: A randomized, double-blind evaluation of the efficacy and safety of two dosing regimens of Integrelin versus placebo for reducing mortality and myocardial re-infarction in patients with unstable angina or non-Qwave myocardial infarction.

Principal Investigator
Rapport: ReoPro in acute myocardial infarction and primary PTCA organization and randomized trial.

Principal Investigator
SHOCK (Should We Emergently Revascularize Occluded Coronaries For Cardiogenic Shock): An international randomized trial of emergency PTA/CABG.

Principal Investigator
STARS (Stent Anti-Thrombotic Regimen Study).

Principal Investigator
TIMI 10A: A phase 1, open-label, multi-center, dose-escalation, single-dose administration study to determine the pharmacokinetics, pharmacodynamics, safety, and tolerance TNK-t-PA in acute myocardial infarction.

Principal Investigator
TIMI 10B: A phase 2, randomized, ,open-label, multi-center, international, angiographic trial of the efficacy of TNK-t-PA compared with accelerated Activase in acute myocardial infarction.

Principal Investigator
TIMI 12: A phase 2, multi-center, randomized, double-blind, aspiring-controlled study to evaluate pharmacokinetic, pharmacodynamics, and safety of Ro48-3657 an oral platelet glycoprotein IB/IIIa antagonist in subjects post and acute coronary syndrome.